The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma
Background GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents the synthesis of leukotrienes and 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE). Objective To assess the effect of GSK2190915 on the allergen-induced asthmatic responses. Methods Nineteen eligible male subjects with mild asthma were enrolled in and completed this four-centre, double-blind, two-way crossover s